E-GEOD-39606 - Gene expression data in CD4+ and CD8+ cells in sarcoidosis patients following antimycobacterial therapy

Released on 23 July 2013, last updated on 2 June 2014
Homo sapiens
Samples (20)
Array (1)
Protocols (6)
Many chronic cutaneous diseases associated with microbial antigens demonstrate clinical progression due to T cell hyporesponsiveness. Appropriate antimicrobial therapy restores T cell function, leading to clinical resolution. Due to the association of sarcoidosis with mycobacterial antigens, we compared the efficacy of antimycobacterial therapy with placebo in chronic cutaneous sarcoidosis. We conducted a randomized, placebo-controlled, single-blind trial on chronic cutaneous sarcoidosis subjects. Participants received the oral CLEAR regimen: Levofloxacin 750 mg on day 1, then 500 mg daily, Ethambutol 1200 mg daily, Azithromycin 500 mg on day 1, then 250 mg daily, and Rifampin 300 mg daily, or a comparative placebo regimen, for a total of 8 weeks, with a 180 day follow-up. Participants were monitored for absolute change in lesion diameter and decrease in granulomas burden upon completion of therapy.
Experiment type
transcription profiling by array 
Kusum Vijay Pandit <panditkv@upmc.edu>, Kusum V Pandit, Naftali Kaminski, Wonder Drake
Investigation descriptionE-GEOD-39606.idf.txt
Sample and data relationshipE-GEOD-39606.sdrf.txt
Raw data (1)E-GEOD-39606.raw.1.zip
Processed data (1)E-GEOD-39606.processed.1.zip
Array designA-GEOD-14550.adf.txt